Definition
454 Life Sciences was a biotechnology company that developed and commercialized high-throughput DNA sequencing technologies, most notably the 454 pyrosequencing platform, which was one of the first next‑generation sequencing (NGS) systems available to research laboratories.
Overview
Founded as a division of Roche Applied Science in the early 2000s, 454 Life Sciences introduced the GS20 and subsequent GS FLX sequencers, enabling massively parallel sequencing of DNA fragments using pyrosequeneration. The technology produced longer reads than contemporary Illumina platforms, which made it valuable for de novo genome assembly, metagenomics, and targeted resequencing. In 2007, Roche fully acquired the company, branding the platform under the "Roche 454" name. Competition from newer NGS technologies and declining market share led Roche to discontinue the 454 platform in 2013 and to sell related assets to other life‑science firms.
Etymology/Origin
The “454” designation derives from the original instrument model number (GS20) and the name of the “454” sequencing chemistry that involved detecting light emitted during nucleotide incorporation. The term was adopted as a brand identifier for the company’s sequencing products.
Characteristics
| Feature | Description |
|---|---|
| Sequencing method | Pyrosequencing – enzymatic incorporation of nucleotides releases pyrophosphate, which triggers a luciferase‑mediated light signal proportional to the number of bases added. |
| Read length | Early GS20 runs produced reads of ~100 bp; later GS FLX Titanium chemistry reached average read lengths of 400–800 bp, with maximum reads exceeding 1 kb. |
| Throughput | Up to 1 Gb per run for the GS FLX Titanium system, markedly lower than contemporary Illumina platforms but sufficient for many small‑genome projects at the time. |
| Applications | Whole‑genome sequencing of bacteria and small eukaryotes, amplicon sequencing for microbial diversity studies, transcriptome analysis, and targeted resequencing of genetic regions. |
| Instrument models | GS20, GS FLX, GS FLX Titanium, and later the junior system GS Junior. |
| Status | Discontinued in 2013; the technology’s intellectual property and some hardware were sold to other companies, with the brand no longer active. |
Related Topics
- Next‑generation sequencing (NGS) – broader category of high‑throughput DNA sequencing technologies.
- Pyrosequencing – the biochemical principle underlying 454 sequencing.
- Roche Applied Science – parent organization that owned 454 Life Sciences during its commercial peak.
- Illumina sequencing – competing NGS platform that eventually dominated the market.
- Metagenomics – an application area that benefitted from the longer reads provided by 454 sequencing.
Note: The information presented reflects documented historical data on 454 Life Sciences and its technology as recorded in scientific literature and corporate histories.